Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) EBIT Margin (2021 - 2025)

Historic EBIT Margin for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Q3 2025 value amounting to 12.24%.

  • Tarsus Pharmaceuticals' EBIT Margin rose 400500.0% to 12.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 23.88%, marking a year-over-year increase of 845900.0%. This contributed to the annual value of 65.9% for FY2024, which is 7546300.0% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its EBIT Margin stood at 12.24% for Q3 2025, which was up 400500.0% from 21.61% recorded in Q2 2025.
  • Tarsus Pharmaceuticals' 5-year EBIT Margin high stood at 33.07% for Q2 2021, and its period low was 4274.56% during Q4 2021.
  • In the last 5 years, Tarsus Pharmaceuticals' EBIT Margin had a median value of 81.6% in 2024 and averaged 775.46%.
  • The largest annual percentage gain for Tarsus Pharmaceuticals' EBIT Margin in the last 5 years was 41239500bps (2022), contrasted with its biggest fall of -36537500bps (2022).
  • Over the past 5 years, Tarsus Pharmaceuticals' EBIT Margin (Quarter) stood at 4274.56% in 2021, then soared by 96bps to 150.61% in 2022, then plummeted by -126bps to 339.94% in 2023, then surged by 89bps to 36.77% in 2024, then soared by 67bps to 12.24% in 2025.
  • Its EBIT Margin stands at 12.24% for Q3 2025, versus 21.61% for Q2 2025 and 33.55% for Q1 2025.